Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease

Similar documents
What is Alzheimer s disease

Diagnosis and assessment

What is Vascular Dementia

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

Drug treatments for Alzheimer s disease

If you have dementia, you may have some or all of the following symptoms.

Medications for Alzheimer s disease: are they right for you?

What is Korsakoff s Syndrome

What is Aids related cognitive impairment

Memory loss in dementia

Hallucinations and Delusions

Understanding Dementia

Medication for Dementia (Acetylcholinesterase Inhibitors)

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

The progression of dementia

Resources: Types of dementia

What is dementia? alzheimers.org.uk

Encourage independence. Please contact the DEMENTIA SA Office

Dental care and dementia

Understanding dementia

Aggressive behaviour. Aggressive behaviour-english-as2-july2010-bw PBO NPO

There are several reasons why a person with dementia may have a poor appetite and seem uninterested in eating.

Walking about or wandering

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia

RISK FACTORS FOR DEMENTIA

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

Donepezil, Galantamine, Rivastigmine and Memantine

Alzheimer s disease Treatment options

Forgetfulness: Knowing When to Ask for Help

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Psychotropic Strategies Handout Package

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Pregabalin. For the Treatment of Pain

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217

WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by

Manufacturer Comments Clinical Evidence Review Report and Supplemental Update and Pharmacoeconomic Review Report

Shared Care Agreement for Donepezil

What is dementia? Symptoms. alzheimers.org.uk

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Community Pharmacy Dementia Audit

Treatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers

Appendix K: Evidence review flow charts

Dr. Adeniyi Mofoluwake and Stacy Kramer

Essential Shared Care Agreement Drugs for Dementia

PACKAGE LEAFLET: INFORMATION FOR THE USER

Alzheimer Disease Agents Drug Class Prior Authorization Protocol

ASK IF NAMZARIC MAY BE RIGHT FOR THEM.

Essential Shared Care Agreement Drugs for Dementia

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine

Memory Loss, Dementia and Alzheimer's Disease: The Basics

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Duloxetine. For the Treatment of Pain

Dementia Support. Your guide to local support in the Royal Borough of Greenwich. Royal Borough of Greenwich May Supported by

Dementia. Memory Evaluation Center Neurology

Leflunomide Treatment Rheumatology Patient Information Leaflet

Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy

Controlled Substance and Wellness Agreement

Package leaflet: Information for the user

NHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Carbamazepine. For the Treatment of Pain

4/11/2017. The impact of Alzheimer s disease. Typical changes. The impact of Alzheimer s disease. Problematic changes. Problematic changes

If your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment.

10 symptoms of caregiver stress

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)

This information explains the advice about supporting people with dementia and their carers that is set out in NICE SCIE clinical guideline 42.

EFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY

Presenter. Dr. Ronald Lucchino

A new model for prescribing varenicline

TRANSPARENCY COMMITTEE

General Health Checkups. Eyes, ears and teeth

Buprenorphine Patch (Transtec Patch)

Package leaflet: Information for the user. ARICEPT 10 mg Film Coated Tablets (Donepezil Hydrochloride)

SMOKING CESSATION IS HARD

Medication Information for Parents and Teachers

Use of steroids in neurological conditions. Information for patients Pharmacy

Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital

Understanding Dementia

SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA

Treatment of Alzheimer s disease

Alzheimer s Disease: Getting the Facts

Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment

Drugs used to relieve behavioural and psychological symptoms in dementia

Alzheimer s disease. The facts in brief

Dementia data harmonisation: South of England Protocol

Patient Guide. This PATIENT GUIDE comes with your Binosto 70mg Effervescent Tablets pack. Please read it carefully.

Coping with Alzheimer s Disease in the Internet Age Survey Results

Dementia and cognitive decline

The most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M.

Donepezil, Rivastigmine and Galantamine (TLS Amber with shared care) Donepezil (TLS green Wilts)

SHARED CARE GUIDELINE FOR TREATMENT OF DEMENTIA 1. Aim/Purpose of this Guideline

PATIENT INFORMATION BOOKLET

Medication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.

Duloxetine for the treatment of pain

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Baylor AT&T Memory Center 9101 N. Central Expressway, Suite 230 Dallas, Texas Phone: (214) Fax: (214)

Thrombosis and Anticoagulation Team. Warfarin. Information for patients, relatives and carers

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

Medicines to treat pain in adults. Information for patients and carers

Tuscarawas County Health Department. Vivitrol Treatment Consent

ESCA: Cinacalcet (Mimpara )

PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS

Transcription:

PBO 930022142 NPO 049-191 Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease Aricept, Exelon and Reminyl are not cures for Alzheimer s disease. However, they can temporarily slow down the progression of symptoms in people in the early to middle stages of the disease. How do these new drugs work? Research has shown that there is not enough of a chemical called acetylcholine in the brains of people with Alzheimer s disease. Acetylcholine is one of the chemicals nerve cells use to communicate. Aricept, Exelon and Reminyl are called acetylcholinesterase inhibitors. They prevent an enzyme known as acetylcholinesterase from breaking down acetylcholine in the brain. Increased concentrations of acetylcholine lead to increased communication between nerve cells which may in turn temporarily improve or stabilize the symptoms of Alzheimer s disease. How do the drugs differ from each other? Aricept, Exelon and Reminyl work in similar ways. However, Reminyl also appears to act on the nicotinic neuronal receptors in the body, making them release more acetylcholine. It is possible that one of these drugs might suit an individual better than another. The specialist should be able to advise whether there is any advantage associated with a particular drug. Are they effective for all people with Alzheimer s disease? At present Aricept, Exelon and Reminyl are only used in people with mild to moderate Alzheimer s disease. They are not effective for everyone and will only temporarily improve memory or delay memory loss. Research is being undertaken to find out whether any of these drugs may be effective in the later stages of Alzheimer s disease.

Are there any side effects? Not everyone has the same side effects or has them for the same length of time. The most frequent side effects include nausea and vomiting, diarrhoea, stomach cramps and headaches, dizziness, fatigue, insomnia and loss of appetite. Ref. images.theage.com How and where can these drugs be obtained? These drugs need to be prescribed by your Psychiatrist or Neurologist. It is also important to discuss with the doctor any possible benefits, risks or side effects. Some people will improve, some will not, while others will continue o deteriorate. Are these drugs effective for other types of dementia? This type of drug was developed specifically to treat Alzheimer s disease. We do not yet know whether they can be helpful for people with other forms of dementia, although there is evidence that they may be effective in dementia with Lewy Bodies and even vascular dementia. Research is continuing. What are the benefits of the drugs? It is impossible to predict the potential benefits of using any of these drugs. Some people will improve, some will not, while others will continue to deteriorate. In cases where these drugs prove effective they appear to slow down the progression of symptoms, including memory loss. They can also improve mood, reduce anxiety and restore confidence. People who do not show an improvement or slowing down in the first few months are unlikely to show any benefit later on. In these cases the drugs will be stopped.

Taking the drugs It may be helpful if the consultant seeks the carer s views of the person s condition before treatment and during follow-up appointments. The patient s views should also be sought. The consultant will also need to be sure that the patient takes their medication regularly. Dosages vary. Usually a patient will start on a low dose, which will be increased later to maximize effectiveness. It is important to be on the highest tolerable dose to get the maximum effect. Aricept is administered once a day and can be taken with or without food. It is available in 5mg or 10mg tablets. Exelon is taken twice a day, normally in the morning and evening. People start with 3mg per day which will usually increase to a dosage of between 6mg to 12mg. Reminyl is taken twice daily with food and is available in 4mg, 8mg and 12mg tablets. The recommended stating dose is 8mg to be taken daily for at least four weeks. What questions should you ask your doctor? What are the potential benefits of taking these drugs? How long will it be before I see a result? How often do these drugs need to be taken? What should I do if a dose is missed? If there are side effects should the drug be stopped immediately? What happens if the drug is stopped suddenly? What other treatments (prescription and over-the-counter) might interact with these drugs?

Any changes in health should be reported immediately How often will visits to the clinic/surgery be needed? Can someone with Alzheimer s disease living in a residential or nursing home take these drugs? Are there any costs associated with taking these drugs? Why is one drug prescribed rather than another? If one drug proves ineffective can another drug be tried? Notes on drugs Aricept (donepezil hydrochloride), produced by Eisai and co-marketed with Pfizer, was the first drug to be licensed in the UK specifically for Alzheimer s disease. Exelon (rivastigmine), produced by Novartis Pharmaceuticals, was the second drug licensed in the UK specifically for Alzheimer s disease. Reminyl (galantamine) was co-developed by Shire Pharmaceuticals and the Janssen Research Foundation. Originally derived from the bulbs of snowdrops and narcissi, Reminyl was the third drug licensed in the UK specifically for Alzheimer s disease. Notes :

Notes: Contact us: 3rd Floor, State House, 3 Rose Street, Cape Town Tel: (021) 421 0077/78 Email: info@dementiasa.org Or support@dementiasa.org P.O. Box 16421 Vlaeberg 8018 www.dementiasa.org